Parkinson's Disease Is Associated with Impaired Gut-Blood Barrier for Short-Chain Fatty Acids
- PMID: 35607987
- DOI: 10.1002/mds.29063
Parkinson's Disease Is Associated with Impaired Gut-Blood Barrier for Short-Chain Fatty Acids
Abstract
Background: Short-chain fatty acids (SCFAs) produced by gut microbiota are reduced in feces but paradoxically increased in plasma of patients with Parkinson's disease (PD), which may stem from intestinal wall leakage. Gut function should be taken into consideration when conducting microbial-metabolite research.
Objective: The objective was to investigate synchronous changes of SCFAs in feces and plasma of patients with PD, taking constipation as a confounder to better disentangle the SCFA metabolism exclusively associated with PD.
Methods: The concentrations of fecal and plasma SCFAs in 33 healthy control subjects and 95 patients with PD were measured using liquid and gas chromatography mass spectrometry, respectively. Patients with PD were divided into patients with PD without constipation (n = 35) and patients with PD with constipation (n = 60). Gut-blood barrier (GBB) permeability was assessed by plasma/fecal ratio of SCFA concentrations and fecal α1-antitrypsin concentration.
Results: Patients with PD displayed decreased concentrations of fecal acetic, propionic, and butyric acid and increased concentrations of plasma acetic and propionic acid. Fecal acetic, isobutyric, and isovaleric acid were lower and plasma acetic and propionic acid were higher in patients with PD with constipation than in patients with PD without constipation. Constipation aggravated GBB permeability in patients with PD. Combined fecal and plasma SCFAs could discriminate patients with PD from healthy control subjects. Fecal SCFAs, except propionic acid, were negatively correlated with disease severity, while plasma acetic, propionic, and valeric acid showed a positive correlation.
Conclusions: Our study showed alterations of fecal and plasma SCFAs in patients with PD that were associated with an impaired GBB and might be aggravated by constipation. © 2022 International Parkinson and Movement Disorder Society.
Keywords: Parkinson's disease; constipation; gut-blood barrier permeability; short-chain fatty acid.
© 2022 International Parkinson and Movement Disorder Society.
Comment in
-
Reply to: "Epigenetic Drug Effects in Levodopa Treated Patients with Parkinson's Disease".Mov Disord. 2023 Apr;38(4):711. doi: 10.1002/mds.29368. Mov Disord. 2023. PMID: 37061883 No abstract available.
-
Epigenetic Drug Effects in Levodopa-Treated Patients with Parkinson's Disease.Mov Disord. 2023 Apr;38(4):710-711. doi: 10.1002/mds.29365. Mov Disord. 2023. PMID: 37061885 No abstract available.
References
-
- Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006;396(1):67-72.
-
- Cersosimo MG, Raina GB, Pecci C, et al. Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. J Neurol 2013;260(5):1332-1338.
-
- Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol 2016;79(6):940-949.
-
- Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007;33(6):599-614.
-
- Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 2016;167(6):1469-1480.e1412.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical